<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="numerous small molecular drugs that are being used for the" exact="treatment" post="of diseases like SARS, MERS, HIV, ebola, malaria, and"/>
 <result pre="to their pathogenicity and immunogenicity and also focuses on various" exact="treatment" post="strategies that could be employed for curing COVID-19. coronavirus"/>
 <result pre="spread, where it took months to identify the cause of" exact="infection" post="and perform genome sequencing (7), advancement in science and"/>
 <result pre="immediate scientific inputs helped with developing diagnostic kits and defining" exact="treatment" post="strategies for effective prognosis and prevention (8â€&quot;10). In this"/>
 <result pre="NSP2 &amp;amp; NSP3 are also believed to impart the enhanced" exact="infection" post="abilities of the novel coronavirus (16, 17). RNA viruses"/>
 <result pre="with a health history, such as those immune-compromised by HIV" exact="infection" post="or by chemotherapy for cancer. Diabetic and asthma patients,"/>
 <result pre="host innate immune cells is impaired during SARS-CoV and MERS-CoV" exact="infection" post="by their non-structural proteins, which affects the overall cytokine"/>
 <result pre="N-specific neutralizing antibody production at an early stage of acute" exact="infection" post="(59). SARS-CoV-specific IgA, IgG, and IgM antibodies were detected"/>
 <result pre="days (63). Another kinetic study of viral shedding and antibody" exact="detection" post="was published in a preprint and reported the presence"/>
 <result pre="studies propose that IgM-based ELISA can be used for early" exact="diagnosis" post="of patients along with qPCR techniques to improve the"/>
 <result pre="The SARS-CoV-2 virus infects through the naso-oral route, followed by" exact="infection" post="in cells expressing ACE2 receptor in the lung, such"/>
 <result pre="and pneumonia. Cytotoxic T cells recruited to the site of" exact="infection" post="try to kill virus-infected cells in the lungs. B"/>
 <result pre="are numerous non-neutralizing antibodies in the system that aid the" exact="infection" post="of immune cells and APCs. Previously existing SARS-CoV antibodies"/>
 <result pre="and APCs. Previously existing SARS-CoV antibodies may promote the viral" exact="infection" post="in FcR-expressing cells (66). This ACE2-independent pathway of viral"/>
 <result pre="of the odds in the pursuit of developing vaccines and" exact="treatment" post="regimens involving antibodies (70). Antigen Presentation During viral infection,"/>
 <result pre="the HLA-DRB1*03, HLA-A*02, and HLA-Cw*15 haplotypes are protected from SARS-CoV" exact="infection" post="(74). Similarly, HLA-DRB1*11 and HLA-DQB1*02 were found to be"/>
 <result pre="HLA-DRB1*11 and HLA-DQB1*02 were found to be vulnerable to MERS-CoV" exact="infection" post="(75). Additionally, MHC expression is also found to be"/>
 <result pre="MHC expression is also found to be reduced during the" exact="infection" post="due to epigenetic modifications of downstream molecules (76, 77)."/>
 <result pre="infection, and this could be crucial for the prevention and" exact="treatment" post="of COVID-19. However, in a recent report, blood plasma"/>
 <result pre="evade the immune response by epigenetically modifying calnexin promoter. But" exact="infection" post="with influenza virus in these cancer cells results in"/>
 <result pre="models by assessing the lung pathology and T-cell response upon" exact="infection" post="in BALB/c and C57BL/6 mice (80, 83). The sequence"/>
 <result pre="Cytokine Production A rapid and coordinated immune response during viral" exact="infection" post="leads to enhanced secretion of various cytokines, which acts"/>
 <result pre="IL-6, and IFN-Î±/-Î³, with reduced anti-inflammatory cytokines (86â€&quot;88). Similarly, MERS-CoV" exact="infection" post="leads to delayed but increased production of IFN-Î± and"/>
 <result pre="chemokines (IP-10, CCL2/MCP1, CXCL1, CXCL5) were also detected in SARS-CoV-2" exact="infection" post="(96â€&quot;99). In children, the increased inflammatory markers include IL-6,"/>
 <result pre="promoters (109â€&quot;111) (Figure 3). A new investigation revealed that SARS-CoV-2" exact="infection" post="leads to an overall decrease in the transcription of"/>
 <result pre="severity (112). In addition to reduction in T cells, SARS-CoV-2" exact="infection" post="also enhances the exhaustion of effector T cells, decreasing"/>
 <result pre="T cells help in destroying the infected cells during subsequent" exact="infection" post="(116, 117). Case studies in recovered SARS patients showed"/>
 <result pre="developed by CRISPR/Cas9 technology that recapitulates the human symptoms upon" exact="infection" post="with SARS-CoV-2 through the intra-nasal route. This tool will"/>
 <result pre="for COVID-19 as of June 15, 2020 (123). Currently, the" exact="treatment" post="regime focuses mainly on providing intensive care in order"/>
 <result pre="mechanisms behind its enhanced pathogenicity might help in developing specific" exact="treatment" post="approaches for COVID-19 in the future. Table 1 List"/>
 <result pre="future. Table 1 List of drugs and vaccines for the" exact="treatment" post="of COVID-19. Targets Description References MONOCLONAL ANTIBODY THERAPY S230.15"/>
 <result pre="Agents Considering the studies on the molecular mechanism of coronavirus" exact="infection" post="(147), several antiviral drugs could be repurposed for the"/>
 <result pre="infection (147), several antiviral drugs could be repurposed for the" exact="treatment" post="of COVID-19. Remdesivir is a nucleotide analog that acts"/>
 <result pre="remdesivir. The preliminary outcomes of the trial reported that remdesivir" exact="treatment" post="decreased the median recovery time in the treatment group"/>
 <result pre="that remdesivir treatment decreased the median recovery time in the" exact="treatment" post="group (11 days) as compared to the placebo group"/>
 <result pre="(15 days). The mortality rate was also less in the" exact="treatment" post="group (7.1%) in contrast to the placebo group (11.9%)"/>
 <result pre="potential nucleoside analogs that might be useful against novel coronavirus" exact="infection" post="(154). The combinatorial therapy approach of using remdesivir along"/>
 <result pre="placebo as a prophylactic measure. The results revealed that hydroxychloroquine" exact="treatment" post="had the same effect as did the placebo group."/>
 <result pre="in minor side effects (40.1%) as compared to the placebo" exact="treatment" post="(6.8%). However, no cardiovascular disorder or treatment-related major complications"/>
 <result pre="it has a great potential for prophylaxis, not to prevent" exact="infection" post="but to reduce effective viral load in patients and"/>
 <result pre="study (169). As with transfusion of any blood products, precautionary" exact="screening" post="of infectious agent is warranted in plasma transfusion. Recently,"/>
 <result pre="in animal models (175) and could be potential candidates for" exact="testing" post="against SARS-CoV-2. A recent pilot study with a purified"/>
 <result pre="10 different strains of SARS-CoV-2 without developing any ADE of" exact="infection" post="(176). Various randomized controlled trials (NCT04327206, NCT04328441) are also"/>
 <result pre="IFN-Î³, which further contributes to conferring protective immunity against SARS-CoV-2" exact="infection" post="(184). Recently, a monoclonal antibody (47D11) has been identified"/>
 <result pre="S1 subunit vaccine, which could be really helpful in the" exact="treatment" post="of the emerging COVID-19 outbreak (187). The transfer of"/>
 <result pre="A previous study in a MERS animal model showed that" exact="treatment" post="with recombinant type-1 IFN (rIFN) decreased the viral RNA"/>
 <result pre="in lungs with a decrease in IFN-stimulating gene expression. Early" exact="treatment" post="with rIFN resulted in a dampening of cytokine and"/>
 <result pre="every country have approved guidelines and taken necessary action to" exact="quarantine" post="infected people and break the chain of community spread."/>
 <result pre="attempted to determine the efficacy of these antibodies in the" exact="treatment" post="of SARS-CoV-2 infection. Clinical trial ChiCTR2000029765 with tocilizumab, a"/>
 <result pre="Emerg Infect Dis. (2004) 10:20â€&quot;4. 10.3201/eid1001.03040415078592 46.GuJGongEZhangBZhengJGaoZZhongYet al.. Multiple organ" exact="infection" post="and the pathogenesis of SARS. J Exp Med. (2005)"/>
 <result pre="Med. (2020) 382:4â€&quot;6. 10.1056/NEJMc121000131800980 48.ZhangZGuoLLuXZhangCWangXHuangLet al.Vulnerability of children with COVID-19" exact="infection" post="and ACE2 profiles in lungs. SSRN. (2020) 1:1â€&quot;18. 10.2139/ssrn.3602441"/>
 <result pre="coronavirus. Pediatr Res. (2020) 145:2020. 10.1038/s41390-020-0892-832268343 50.ChenZMFuJFShuQChenYHHuaCZLiFBet al.. Diagnosis and" exact="treatment" post="recommendations for pediatric respiratory infection caused by the 2019"/>
 <result pre="10.1038/s41390-020-0892-832268343 50.ChenZMFuJFShuQChenYHHuaCZLiFBet al.. Diagnosis and treatment recommendations for pediatric respiratory" exact="infection" post="caused by the 2019 novel coronavirus. World J Pediatr."/>
 <result pre="Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19)" exact="infection" post="admitted to US and canadian pediatric intensive care units."/>
 <result pre="Clin Diagn Lab Immunol. (2004) 11:362â€&quot;71. 10.1128/CDLI.11.2.362-371.200415013989 58.WuHSHsiehYCSuIJLinTHChiuSCHsuYFet al.. Early" exact="detection" post="of antibodies against various structural proteins of the SARS-associated"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2 : an observational cohort study. Lancet Infect"/>
 <result pre="(2020) 1â€&quot;24. 10.20944/preprints202003.0138.v1 68.YipMLeungHLiPCheungCDutryILiDet al.. Antibody-dependent enhancement of SARS coronavirus" exact="infection" post="and its role in the pathogenesis of SARS. Hong"/>
 <result pre="Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus" exact="infection" post="in the hospital with the highest nosocomial infection rate"/>
 <result pre="syndrome coronavirus infection in the hospital with the highest nosocomial" exact="infection" post="rate in Taiwan in 2003. J Clin Microbiol. (2006)"/>
 <result pre="Med. (2016) 11:211â€&quot;3. 10.4103/1817-1737.18575627512511 76.JossetLMenacheryVDGralinskiLEAgnihothramSSovaPCarterVSet al.. Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
 <result pre="IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomes. J Clin Invest. (2019) 129:3625â€&quot;39. 10.1172/JCI12636331355779 92.NgDLAl HosaniFKeatingMKGerberSIJonesTLMetcalfeMGet"/>
 <result pre="of a fatal case of middle east respiratory syndrome coronavirus" exact="infection" post="in the United Arab Emirates, April 2014. Am J"/>
 <result pre="patients. Natl Sci Rev. (2020) 7:1â€&quot;5. 10.1093/nsr/nwaa041 98.WenZhangYanZhaoFengchunZhangQianWangTaishengLiZhengyinLiuet al.. Anti-inflammation" exact="treatment" post="of severe coronavirus disease 2019 (COVID-19): from the perspective"/>
 <result pre="(2016) 44:1379â€&quot;91. 10.1016/j.immuni.2016.05.00627287409 122.SunSChenQGuHYangGWangYHuangXet al.. A mouse model of SARS-CoV-2" exact="infection" post="and pathogenesis. Cell Host Microbe. (2020) 28:124â€&quot;33.e4. 10.1016/j.chom.2020.05.02032485164 123.ZumlaAChanJFWAzharEIHuiDSCYuenKY."/>
 <result pre="15:327â€&quot;47. 10.1038/nrd.2015.3726868298 124.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
 <result pre="124.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)."/>
 <result pre="April 9, 2020). 131.SallardELescureFXYazdanpanahYMentreFPeiffer-SmadjaN. Type 1 interferons as a potential" exact="treatment" post="against COVID-19. Antiviral Res. (2020) 178:1â€&quot;4. 10.1016/j.antiviral.2020.10479132275914 132.Prokunina-OlssonLAlphonseNDickensonREDurbinJEGlennJSHartmannRet al.."/>
 <result pre="10.1084/jem.2020065332289152 133.MorseJSLalondeTXuSLiuWR. Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoV."/>
 <result pre="Transl Med. (2020) 5883:1â€&quot;21. 10.1126/scitranslmed.abb588332253226 137.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.. Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet. (2020) 395:e30â€&quot;e31. 10.1016/S0140-6736(20)30304-432032529"/>
 <result pre="10.1056/nejmoa200128232187464 140.GuoD. Old weapon for new enemy: drug repurposing for" exact="treatment" post="of newly emerging viral diseases. Virol Sin. (2020) 35:12250."/>
 <result pre="7:1â€&quot;7. 10.1038/srep4339528127051 150.de WitEFeldmannFCroninJJordanROkumuraAThomasTet al.. Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection. Proc"/>
 <result pre="(2020) NEJMoa2007764. 10.1056/NEJMoa2007764 154.De ClercqE. New nucleoside analogues for the" exact="treatment" post="of hemorrhagic fever virus infections. Chem - An Asian"/>
 <result pre="156.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. (2005) 2:1â€&quot;10. 10.1186/1743-422X-2-6915631631 157.SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects"/>
 <result pre="ex vivo culture-expanded adult human mesenchymal stromal cells for the" exact="treatment" post="of pediatric patients who failed to respond to steroid"/>
 <result pre="treatment of pediatric patients who failed to respond to steroid" exact="treatment" post="for acute graft-versus-host disease. Biol Blood Marrow Transplant. (2020)"/>
</results>
